Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Executive Summary

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

You may also be interested in...



Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

US FDA is ‘willing to look at anything’ but sponsors need to demonstrate an effect on pain as drug development challenges remain. Accompanying chart describes 32 drugs in Phase II and Phase III clinical trials and one with a pending biologics license application.

Can An Antibody Cocktail Block COVID-19 Infection? Regeneron’s Warp Speed Research Aims To Find Out Soon

The only non-vaccine project backed by Operation Warp Speed, Regeneron’s antibody cocktail could play a crucial role in the fight against SARS-CoV2 – if it works. Clinical development chief David Weinreich talks to Scrip about its innovative adaptive trial collaboration, and how it could provide answers in a matter of months.

Coronavirus Update: Regeneron Gets Warp Speed Funding, Conflict Slowing Moderna's Progress

Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel